Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2017-12-18T17:40:09+00:00

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

A rights offer for existing shareholders is now open.

Full details are available here.

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Recent news and media

PharmaVentures Interview with Kathy Harrison

Last November, Adrian Dawkes of PharmaVentures interviewed Kathy Harrison, CEO of Dimerix. Kathy discusses the companies focus on developing new therapeutic [...]

Recorded interview with CEO and rights issue reminder

The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 [...]

DMX-200 Dosage Optimisation Study Successfully Completed in Preparation for Phase 2b trial

Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program [...]

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation